The observation that the Mut_48 peptide, containing both a CD4+ and CD8+ T cell epitope, was the most effective NeoAg against a tumor lacking MHC II prompted us to investigate the functional contribution made by Cltc-specific CD4+ T cells toward therapeutic vaccination. This evidence concerns the gene CD4 and neoplasm.